Rohto Pharmaceutical Co (4527) AI Stock Analysis

• Market Cap: $584.69B
• Dividend Yield: 1.42%
• Average Volume (3M): 1.09M
• Price to Earnings (P/E): 16.7
• Beta (1Y): 0.58
• Revenue Growth: 15.90%
• EPS Growth: 13.60%
• Country: JP
• Employees: 7,259
• Sector: Consumer Defensive
• Sector Strength: 53
• Industry: Household & Personal Products
• EPS (TTM): 52.09
• Shares Outstanding: 236,178,310
• 10 Day Avg. Volume: 1,104,480
• 30 Day Avg. Volume: 1,093,323
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.77
• Enterprise Value/Revenue: 1.53
• Enterprise Value/Gross Profit: 2.68
• Enterprise Value/Ebitda: 9.93
• 1Y Price Target: $2,610.23
• Price Target Upside: 2.81% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5

• Rating: 76 Outperform
• Price Target: ¥2,413.00 ▼(-4.96% Downside)

Rohto Pharmaceutical's strong financial performance is the primary driver of its overall score, supported by solid technical indicators and reasonable valuation metrics. The company's robust financials, coupled with positive market momentum, position it well within the industry.

Rohto Pharmaceutical Co Business Overview & Revenue Model

Company Description

Rohto Pharmaceutical Co.,Ltd. manufactures and markets pharmaceutical products, cosmetics, and functional foods worldwide. The company provides eye care products, such as eye drops, care for contact lenses, and eye wash; and facial care products comprising face wash, lotions, and creams. It also offers medicine and medicated products for skin; medicine for internal use, such as digestive and herbal medicines; oral medicines comprising gastrointestinal medicines, herbal medicines, and supplements; non-prescription medicines; and beauty counters that provide beauty and health services. The company was formerly known as Yamada Pharmaceutical and changed its name to Rohto Pharmaceutical Co.,Ltd. in September 1949. Rohto Pharmaceutical Co.,Ltd. was founded in 1899 and is headquartered in Osaka, Japan.

How the Company Makes Money

Rohto Pharmaceutical Co. generates revenue through the sale of its diversified portfolio of over-the-counter medications and consumer healthcare products. The company's primary revenue streams include its eye care products, such as eye drops, and skincare lines, which are popular across various international markets. Additionally, Rohto earns from its pharmaceutical products, including gastrointestinal and anti-inflammatory drugs. Significant partnerships and distribution agreements with retailers and pharmacies enhance its market presence and contribute to its sales. The company's strategic global expansion and innovation in product development also play crucial roles in driving its financial performance.

Rohto Pharmaceutical Co Financial Statement Overview

Summary

Rohto Pharmaceutical exhibits strong financial health with consistent revenue growth, solid profit margins, a robust balance sheet, and effective cash flow management. The company's low debt-to-equity ratio and high equity ratio further indicate financial stability and efficient capital utilization.

Income Statement

Rohto Pharmaceutical has shown a consistent upward trend in revenue growth, with a notable increase of 13.94% in the latest year. Gross profit margin remains strong at 54.88%, and the net profit margin is stable at 10.05%. Despite a slight dip in EBIT margin to 12.46%, the company maintains healthy profitability metrics overall.

Balance Sheet

The company's balance sheet is robust, highlighted by a low debt-to-equity ratio of 0.19, indicating low leverage and financial stability. The equity ratio is healthy at 61.64%, suggesting a strong capital structure. Return on equity stands at 11.92%, showcasing efficient use of equity to generate profit.

Cash Flow

Rohto Pharmaceutical has demonstrated solid cash flow management with a free cash flow growth rate of 9.90%. The operating cash flow to net income ratio is healthy at 1.19, indicating strong cash generation relative to net income. The free cash flow to net income ratio is also favorable at 0.90.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	308.63B	270.84B	238.66B	199.65B	181.05B
Gross Profit	169.38B	157.29B	137.42B	116.49B	106.73B
EBITDA	56.42B	50.40B	41.34B	35.81B	28.61B
Net Income	31.00B	30.94B	26.38B	21.13B	16.74B
Balance Sheet
Total Assets	421.88B	346.18B	309.68B	274.63B	225.79B
Cash, Cash Equivalents and Short-Term Investments	77.16B	89.21B	79.95B	72.79B	52.96B
Total Debt	50.22B	10.49B	11.69B	21.38B	8.10B
Total Liabilities	150.43B	99.14B	94.60B	90.80B	69.18B
Stockholders Equity	260.10B	246.32B	209.57B	178.28B	155.91B
Cash Flow
Free Cash Flow	27.84B	25.33B	21.02B	15.92B	9.70B
Operating Cash Flow	36.92B	34.24B	30.92B	27.25B	20.01B
Investing Cash Flow	-57.55B	-16.32B	-13.18B	-16.41B	-10.24B
Financing Cash Flow	3.70B	-13.78B	-16.20B	3.47B	-2.35B

Rohto Pharmaceutical Co Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2539.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4527, the sentiment is Positive. The current price of 2539 is above the 20-day moving average (MA) of 2320.37, above the 50-day MA of 2164.47, and above the 200-day MA of 2421.99, indicating a bullish trend. The MACD of 116.10 indicates Negative momentum. The RSI at 72.24 is Negative, neither overbought nor oversold. The STOCH value of 83.30 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4527.

Rohto Pharmaceutical Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4527	76 Outperform	$584.69B	16.68	13.33%	1.42%	15.90%	13.60%
Sector *	63 Neutral	$20.91B	14.58	-4.08%	3.07%	2.70%	-8.71%
KBYPF	―	$2.76B	34.92	5.72%	1.79%	―	―
KOSCF	―	$2.27B	112.89	1.11%	1.04%	―	―
LIOPF	―	$3.09B	22.44	7.29%	1.92%	―	―
PORBF	―	$2.01B	46.09	3.99%	3.40%	―	―
4911	58 Neutral	¥1.01T	496.62		2.02%	-3.60%	-112.93%

Rohto Pharmaceutical Co Corporate Events

Rohto Pharmaceutical Revises Earnings Forecast Upward

Rohto Pharmaceutical Co., Ltd. has revised its earnings forecast for the fiscal year ending March 31, 2026, reflecting an increase in ordinary income and profit attributable to owners due to dividend income recorded in the first quarter. The revised forecast indicates a 6.2% increase in ordinary income and a 1.3% increase in profit attributable to owners compared to the previous forecast, with exchange rates remaining stable.

Rohto Pharmaceutical Reports Strong Q1 Financial Performance with Revised Forecast

Rohto Pharmaceutical Co. reported a significant increase in net sales by 19.9% for the first quarter ending June 30, 2025, compared to the previous year. Despite a slight decrease in operating income, the company saw a substantial rise in ordinary income and profit attributable to owners of the parent, indicating a strong financial performance. The company also revised its full-year financial forecast upwards, reflecting the finalization of provisional accounting treatment for a business combination and the inclusion of Rohto MediLuxe Europe S.A.S.U. in its consolidation scope. This strategic move is expected to strengthen Rohto’s market position and enhance shareholder value.

Rohto Pharmaceutical Announces Dividend Increase

Rohto Pharmaceutical Co., Ltd. announced a resolution to pay dividends from retained earnings, with a record date of March 31, 2025. The year-end dividend per share is set at 20 yen, consistent with the most recent forecast, and represents an increase from the previous fiscal year’s 15 yen per share. This decision reflects the company’s strong financial performance and commitment to returning value to shareholders, potentially enhancing its market position and investor confidence.